TATAA specializes in cell and gene therapy bioanalytical assays and biomarker profiling for precision medicine through genomics, transcriptomics, and proteomics services. TATAA’s robust molecular analyses allow biopharma researchers to define drug targets, select patient populations, prioritize drug formulations, and prepare IND filings.
TATAA Biocenter, a leading provider of high-quality molecular analysis services, announced today that it has become a certified Qualified Service Provider for HTG Molecular Diagnostics. This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.
TATAA Biocenter has partnered with Universal Sequencing Technology Corporation (UST) to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.
The LIMS has been set up specifically for the needs of TATAA Biocenter and will stand out to customers as a critical competitive differentiator. A tailored and unique system bringing many benefits to TATAA’s scientists and customers.
As part of a 320M SEK investment program in biological therapies, one research project will play a pivotal role in making Sweden a major leader in Advanced Therapeutic Medical Products (ATMPs) by 2030.
TATAA Biocenter, Europe’s leading provider of molecular analysis services, announced it is adding Stilla’s six-color naica® system to its digital PCR service offerings
Tataa Biocenter is partnering with Olink and Illumina to offer high performance proteomics with unprecedented throughput
© Care Equity Capital Management L.P. New York, New York
